Advanced search
Publication Cover
Expert Opinion on Emerging Drugs Volume 23, 2018 - Issue 4
Submit an article Journal homepage
1,133
Views
40
CrossRef citations to date
0
Altmetric
Review

Emerging drugs for migraine treatment: an update

Giorgio LambruThe Headache Centre, Pain Management and Neuromodulation, Guy’s and St Thomas NHS Foundation Trust, London, UK;The Wolfson CARD, Institute of Psychology, Psychiatry and Neuroscience, King’s College London, London, UKCorrespondence[email protected]
View further author information
,
Anna P. AndreouThe Headache Centre, Pain Management and Neuromodulation, Guy’s and St Thomas NHS Foundation Trust, London, UK;The Wolfson CARD, Institute of Psychology, Psychiatry and Neuroscience, King’s College London, London, UKView further author information
,
Martina GuglielmettiDepartment of Clinical and Molecular Medicine, Sapienza” University, “Sant’Andrea” Hospital, Regional Referral Headache Centre, Rome, ItalyView further author information
&
Paolo MartellettiDepartment of Clinical and Molecular Medicine, Sapienza” University, “Sant’Andrea” Hospital, Regional Referral Headache Centre, Rome, ItalyORCID Iconhttp://orcid.org/0000-0002-6556-4128View further author information
ORCID Icon
Pages 301-318 | Received 27 Sep 2018, Accepted 23 Nov 2018, Published online: 30 Nov 2018

Citations (40)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (6)

Valerio Spuntarelli, Andrea Negro, Michelangelo Luciani, Enrico Bentivegna & Paolo Martelletti. (2021) Eptinezumab for the treatment of migraine. Expert Opinion on Biological Therapy 21:8, pages 999-1011.
Read now
Peer Tfelt-Hansen. (2021) Pharmacological strategies to treat attacks of episodic migraine in adults. Expert Opinion on Pharmacotherapy 22:3, pages 305-316.
Read now
Abimael González-Hernández, Miguel Condés-Lara, Enrique García-Boll & Carlos M. Villalón. (2021) An outlook on the trigeminovascular mechanisms of action and side effects concerns of some potential neuropeptidergic antimigraine therapies. Expert Opinion on Drug Metabolism & Toxicology 17:2, pages 179-199.
Read now
Simy K. Parikh, John G. Burkett & Stephen D. Silberstein. (2020) A comprehensive overview and safety evaluation of fremanezumab as a preventive therapy for migraine. Expert Opinion on Drug Safety 19:5, pages 537-543.
Read now
Luana Lionetto, Martina Curto, Giusy Ylenia Cisale, Matilde Capi, Fabiola Cipolla, Martina Guglielmetti & Paolo Martelletti. (2019) Fremanezumab for the preventive treatment of migraine in adults. Expert Review of Clinical Pharmacology 12:8, pages 741-748.
Read now
Stephen D. Silberstein, Joshua M. Cohen & Paul P. Yeung. (2019) Fremanezumab for the preventive treatment of migraine. Expert Opinion on Biological Therapy 19:8, pages 763-771.
Read now

Articles from other publishers (34)

Giorgio Lambru, Valeria Caponnetto, Bethany Hill, Susanna Ratti, Simona Sacco, Madeleine Murphy, Jessica Briscoe & Anna P. Andreou. (2023) Long-Term Effect of Switching From an Anti-CGRP Receptor to an Anti-CGRP Ligand Antibody in Treatment-Refractory Chronic Migraine: A Prospective Real-World Analysis. Neurotherapeutics 20:5, pages 1284-1293.
Crossref
Horia Pleș, Ioan-Alexandru Florian, Teodora-Larisa Timis, Razvan-Adrian Covache-Busuioc, Luca-Andrei Glavan, David-Ioan Dumitrascu, Andrei Adrian Popa, Andrei Bordeianu & Alexandru Vlad Ciurea. (2023) Migraine: Advances in the Pathogenesis and Treatment. Neurology International 15:3, pages 1052-1105.
Crossref
Shadi Aghamohammad, Asal Hafezi & Mahdi Rohani. (2023) Probiotics as functional foods: How probiotics can alleviate the symptoms of neurological disabilities. Biomedicine & Pharmacotherapy 163, pages 114816.
Crossref
Astrid Gendolla, Nadine Rauer, Susanne Kraemer, Inka Schwerdtner & Andreas Straube. (2021) Epidemiology, Demographics, Triptan Contraindications, and Prescription Patterns of Patients with Migraine: A German Claims Database Study. Neurology and Therapy 11:1, pages 167-183.
Crossref
Adnan Al-Kaisy, Stefano Palmisani, Roy Carganillo, Samuel Wesley, David Pang, Anand Rotte, Angela Santos & Giorgio Lambru. (2022) Safety and Efficacy of 10 kHz Spinal Cord Stimulation for the Treatment of Refractory Chronic Migraine: A Prospective Long-Term Open-Label Study. Neuromodulation: Technology at the Neural Interface 25:1, pages 103-113.
Crossref
Paolo Martelletti. 2022. Migraine in Medicine. Migraine in Medicine 639 881 .
Simy Parikh. 2022. Novel Synthetic Drugs in Migraine. Novel Synthetic Drugs in Migraine 83 95 .
Anna P. Andreou. 2022. Novel Synthetic Drugs in Migraine. Novel Synthetic Drugs in Migraine 33 42 .
Anna P. Andreou. 2022. Glutamate and Neuropsychiatric Disorders. Glutamate and Neuropsychiatric Disorders 195 228 .
Zeya Yan, Tao Xue, Shujun Chen, Xin Wu, Xingyu Yang, Guangjie Liu, Shan Gao, Zhouqing Chen & Zhong Wang. (2021) Different dosage regimens of Eptinezumab for the treatment of migraine: a meta-analysis from randomized controlled trials. The Journal of Headache and Pain 22:1.
Crossref
Michael Ament, Kathleen Day, Virginia L Stauffer, Vladimir Skljarevski, Mallikarjuna Rettiganti, Eric Pearlman & Sheena K. Aurora. (2021) Effect of galcanezumab on severity and symptoms of migraine in phase 3 trials in patients with episodic or chronic migraine. The Journal of Headache and Pain 22:1.
Crossref
Moein Ala, Mehdi Ghasemi, Razieh Mohammad Jafari & Ahmad Reza Dehpour. (2021) Beyond its anti‐migraine properties, sumatriptan is an anti‐inflammatory agent: A systematic review . Drug Development Research 82:7, pages 896-906.
Crossref
Mina Abdolahi, Elmira Karimi, Payam Sarraf, Abbas Tafakhori, Goli Siri, Farahnaz Salehinia, Mohsen Sedighiyan, Behzad Asanjarani, Mostafa Badeli, Hamed Abdollahi, Niyoosha Yoosefi, Abolghasem yousefi, Amir Shayegan rad & Mahmoud Djalali. (2021) The omega-3 and Nano-curcumin effects on vascular cell adhesion molecule (VCAM) in episodic migraine patients: a randomized clinical trial. BMC Research Notes 14:1.
Crossref
Giorgio Lambru, Silvia Benemei, Anna P. Andreou, Michelangelo Luciani, Gianluca Serafini, Antoinette Maassen van den Brink & Paolo Martelletti. (2020) Position Paper on Post-Traumatic Headache: The Relationship Between Head Trauma, Stress Disorder, and Migraine. Pain and Therapy 10:1, pages 1-13.
Crossref
Matilde Capi, Valerio De Angelis, Donatella De Bernardini, Ottavia De Luca, Fabiola Cipolla, Luana Lionetto, Maurizio Simmaco & Paolo Martelletti. (2021) CGRP Receptor Antagonists and 5-HT1F Receptor Agonist in the Treatment of Migraine. Journal of Clinical Medicine 10:7, pages 1429.
Crossref
Anna Ferrari & Cecilia Rustichelli. (2021) Rational Use of Lasmiditan for Acute Migraine Treatment in Adults: A Narrative Review. Clinical Therapeutics 43:4, pages 654-670.
Crossref
JosephLloyd M Res, Maryna Biloshytska, AnnaP Andreou & Giorgio Lambru. (2021) Noninvasive Neuromodulation in Headache: An Update. Neurology India 69:7, pages 183.
Crossref
Chun-Pai Yang, Kuo-Ting Huang, Ching-Mao Chang, Cheng-Chia Yang & Shuu-Jiun Wang. (2021) Acute Treatment of Migraine: What has Changed in Pharmacotherapies?. Neurology India 69:7, pages 25.
Crossref
Byung-Kun Kim, Soo-Jin Cho, Chang-Soo Kim, Fumihiko Sakai, David W. Dodick & Min Kyung Chu. (2021) Disability and Economic Loss Caused by Headache among Information Technology Workers in Korea. Journal of Clinical Neurology 17:4, pages 546.
Crossref
Anna P. Andreou, Charlotte Leese, Rosaria Greco, Chiara Demartini, Eve Corrie, Deniz Simsek, Anna Zanaboni, Ksenia Koroleva, Joseph O. Lloyd, Giorgio Lambru, Ciara Doran, Oleg Gafurov, Elizabeth Seward, Rashid Giniatullin, Cristina Tassorelli & Bazbek Davletov. (2020) Double-Binding Botulinum Molecule with Reduced Muscle Paralysis: Evaluation in In Vitro and In Vivo Models of Migraine. Neurotherapeutics 18:1, pages 556-568.
Crossref
Alejandro Labastida-Ramírez. 2021. Monoclonal Antibodies in Headache. Monoclonal Antibodies in Headache 13 23 .
Rosaria Greco, Roberto De Icco, Chiara Demartini, Anna Maria Zanaboni, Elena Tumelero, Grazia Sances, Marta Allena & Cristina Tassorelli. (2020) Plasma levels of CGRP and expression of specific microRNAs in blood cells of episodic and chronic migraine subjects: towards the identification of a panel of peripheral biomarkers of migraine?. The Journal of Headache and Pain 21:1.
Crossref
Janet H. Ford, Tobias Kurth, Amaal J. Starling, David W. Ayer, Linda A. Wietecha, Martha D. Port, Mallikarjuna Rettiganti & Dustin D. Ruff. (2020) Migraine Headache Day Response Rates and the Implications to Patient Functioning: An Evaluation of 3 Randomized Phase 3 Clinical Trials of Galcanezumab in Patients With Migraine. Headache: The Journal of Head and Face Pain 60:10, pages 2304-2319.
Crossref
Peiwei Hong, Tianlin Tan, Yao Liu & Jing Xiao. (2020) Gepants for abortive treatment of migraine: A network meta‐analysis. Brain and Behavior 10:8.
Crossref
Anna P. Andreou, Matteo Fuccaro & Giorgio Lambru. (2020) The role of erenumab in the treatment of migraine. Therapeutic Advances in Neurological Disorders 13, pages 175628642092711.
Crossref
Mads Barloese & Giorgio Lambru. 2020. Neuromodulation in Headache and Facial Pain Management. Neuromodulation in Headache and Facial Pain Management 227 239 .
Anna P. Andreou & Lars Edvinsson. (2019) Mechanisms of migraine as a chronic evolutive condition. The Journal of Headache and Pain 20:1.
Crossref
Linda D’Antona & Manjit Matharu. (2019) Identifying and managing refractory migraine: barriers and opportunities?. The Journal of Headache and Pain 20:1.
Crossref
Leda Marina Pomes, Martina Guglielmetti, Enrico Bertamino, Maurizio Simmaco, Marina Borro & Paolo Martelletti. (2019) Optimising migraine treatment: from drug-drug interactions to personalized medicine. The Journal of Headache and Pain 20:1.
Crossref
Paolo Martelletti, Lars Edvinsson & Messoud Ashina. (2019) Shaping the future of migraine targeting Calcitonin-Gene-Related-Peptide with the Disease-Modifying Migraine Drugs (DMMDs). The Journal of Headache and Pain 20:1.
Crossref
Kristian Agmund Haanes & Lars Edvinsson. (2019) Pathophysiological Mechanisms in Migraine and the Identification of New Therapeutic Targets. CNS Drugs 33:6, pages 525-537.
Crossref
Katharina Kamm, Andreas Straube & Lars Neeb. (2019) Migräne — Therapie im WandelMigraine — therapy in transition. MMW - Fortschritte der Medizin 161:12, pages 50-58.
Crossref
Damiana Scuteri, Annagrazia Adornetto, Laura Rombolà, Maria Diana Naturale, Luigi Antonio Morrone, Giacinto Bagetta, Paolo Tonin & Maria Tiziana Corasaniti. (2019) New Trends in Migraine Pharmacology: Targeting Calcitonin Gene–Related Peptide (CGRP) With Monoclonal Antibodies. Frontiers in Pharmacology 10.
Crossref
Dominique Valade. (2019) Les avancées dans les traitements de crise et de fond de la maladie migraineuse. Biologie Aujourd'hui 213:1-2, pages 59-64.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.